Abstract:Objective: To investigate the synergistic therapy effects of B and T lymphocyte attenuator (BTLA) extracellular domain in combination with heat shock protein 70 (HSP70)-TC-1 antigen peptide complex on the mouse model of cervical cancer and the related immunological mechanisms. Methods: (1) Detecting the BTLA and herpesvirus entry mediator (HVEM) gene expression in the tumor microenvironment after C57BL/6 mice were inoculated with TC-1 tumor cells by realtime PCR; BTLA, HVEM expression on tumor infiltrating lymphocytes cell surface were detected by flow cytometry (fluorescence intensity). (2) According to different treatments, tumor-bearing mice were divided into 5 groups, which was injected with pcDNA3.1 (empty vector plasmid as control), psBTLA (vector plasmid which expresses BTLA extracellular domain), HSP70 (HSP70-TC-1 cell peptide complex), HSP70 + pcDNA3.1 or HSP70 + psBTLA, respectively. The weight of tumor was recorded. The expression of immunoregulatory genes in tumor microenvironment were detected. The change of lymphocyte amount and cytotoxicity were detected too; lymphocyte proliferation activity was measured by tritium thymidine incorporation assay; the concentration of interleukin (IL)2 and interferon-γ (IFN-γ) in supernatants of spleen lymphocyte were measured by enzyme-linked immunosorbent assay (ELISA). Results: (1) BTLA gene expression was gradually increased after tumor cells inoculation. The highest expression level was 2.83 ± 0.35 at 14th day, which had statistical significance difference with the 7th day expression of 1.66 ± 0.25 (P < 0.05). While HVEM mRNA expression did not change significantly (P > 0.05). The 7th and 14th day after TC-1 cells inoculation, the average fluorescence intensity of BTLA expression on the surface of tumor infiltrating lymphocytes was 33.5 and 51.8, respectively, in which there was statistically significant difference (P < 0.05); while the difference of HVEM expression was not statistically significant (57.2 vs 49.3, P > 0.05). (2) The 28th day after inoculation, tumor inhibition rate of HSP70 + psBTLA group was 88%, which was significantly higher than other treatment groups (P < 0.05). The 28th day after TC-1 cells inoculation, combination therapy not only promoted IFN-γ and IL-2 gene (3.12 ± 0.71, 3.20 ± 0.62) expression but also reduced transforming growth factor-β (TGF-β), Foxp3 and IL-10 expression (0.25 ± 0.03, 0.19 ± 0.03, 0.31 ± 0.04; P < 0.05). It also promoted CD₈(+) T lymphocyte infiltration (52 ± 6)/high power field, cytotoxicity (65.5 ± 2.4)%, proliferation (15.0 × 10³ cpm) and cytokine IL-2, IFN-γ secretion (824 ± 51), (1096 ± 112) pg/ml, which were all significantly higher than other groups (P < 0.05). Conclusion: The effect of immunotherapy on tumor can be augmented by the combination of psBTLA which expresses extracellular domain of BTLA and HSP70-TC-1 tumor antigen peptide complex, which could improve the expression of the related immunoregulatory genes to establish a much better microenvironment in favor of anti-tumor immune response against the mice model of the cervix carcinoma.

Cytotoxicity of specific CTL induced by EBV-LMP2A peptide on human EBV associated gastric carcinoma cell in vitro

Anti-tumor immunity against nasopharyngeal carcinoma by means of LMP2A-specific cytotoxic T lymphocytes induced by dendritic cells.

Anti-nasopharyngeal carcinoma effect in vivo and in vitro of cytotoxicity T lymphocyte induced by Ad5-latent membrane protein 2A]

Early Pattern of Epstein-Barr Virus Infection in Gastric Epithelial Cells by “Cell-in-cell”

Optimization of EBV specific CTLs cell culture system with the combination of IL-17 and IL-15 cytokines in gastric cancer

LMP1-specific cytotoxic T cells for the treatment of EBV-related post-transplantation lymphoproliferative disorders

[T Cells Recognizing EBV-epitopes Arose in Co-Culture of Peripheral Blood Mononuclear Cells from EB-infected Patients and Dendritic Cells Loaded with LMP2-mixed Peptides].

The Efficacy and Safety of Epstein‐Barr Virus‐specific Antigen Peptide‐activated Cytotoxic T‐cells Treatment for Refractory or Recurrent Angioimmunoblastic T‐cell Lymphoma: A Prospective Clinical Observational Study

[Detection of HBV Specific Cytotoxic Lymphocytes Responses in Severe Hepatitis B Patients Using MHC-peptide Tetramer Flow Cytometry].

CRISPR-Cas9-mediated Disruption of PD-1 on Human T Cells for Adoptive Cellular Therapies of EBV Positive Gastric Cancer.

EBV LMP2A-specific T Cell Immune Responses Elicited by Dendritic Cells Loaded with LMP2A Protein

Peripheral Blood Mononuclear Cells Inhibit Proliferation and Promote Apoptosis of HeLa Cells Following Stimulation with Bacillus Calmette-Guerin

In vitro anti-tumor immune response induced by dendritic cells transfected with EBV-LMP2 recombinant adenovirus

Safety and Efficacy of Donor-Derived Virus Specific Cytotoxic T Lymphocytes(CTL) Administered in Treatment for CMV/EBV Infections after Allogenetic Stem Cell Transplantation

Induction of Cytotoxic T Lymphocytes from the Peripheral Blood of a Hepatocellular Carcinoma Patient Using a MAGE-1 Peptide (NYKCRFPEI) in Vitro

Positive Status of Epstein-Barr Virus As a Biomarker for Gastric Cancer Immunotherapy: A Prospective Observational Study

Bleomycin induced EBV-specific gastric epithelial cell death is enhanced by LMP2A

Integrative Identification of Epstein-Barr Virus-Associated Mutations and Epigenetic Alterations in Gastric Cancer.

The implication of tumor-infiltrating lymphocytes in Epstein-Barr virus-associated gastric carcinoma

[Therapeutic effects of B and T lymphocyte attenuator extracellular domain and heat shock protein 70 antigen peptide on cervical cancer in mouse model]

Analysis of Epstein-Barr Viral Dna Load, Ebv-Lmp2 Specific Cytotoxic T-Lymphocytes and Levels of Cd4(+)Cd25(+) T Cells in Patients with Nasopharyngeal Carcinomas Positive for Iga Antibody to Ebv Viral Capsid Antigen